1
|
Tucci ST, Seo JW, Kakwere H, Kheirolomoom A, Ingham ES, Mahakian LM, Tam S, Tumbale S, Baikoghli M, Cheng RH, Ferrara KW. A Scalable Method for Squalenoylation and Assembly of Multifunctional 64Cu-Labeled Squalenoylated Gemcitabine Nanoparticles. Nanotheranostics 2018; 2:387-402. [PMID: 30324084 PMCID: PMC6170330 DOI: 10.7150/ntno.26969] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2018] [Accepted: 09/02/2018] [Indexed: 12/15/2022] Open
Abstract
Squalenoylation of gemcitabine, a front-line therapy for pancreatic cancer, allows for improved cellular-level and system-wide drug delivery. The established methods to conjugate squalene to gemcitabine and to form nanoparticles (NPs) with the squalenoylated gemcitabine (SqGem) conjugate are cumbersome, time-consuming and can be difficult to reliably replicate. Further, the creation of multi-functional SqGem-based NP theranostics would facilitate characterization of in vivo pharmacokinetics and efficacy. Methods: Squalenoylation conjugation chemistry was enhanced to improve reliability and scalability using tert-butyldimethylsilyl (TBDMS) protecting groups. We then optimized a scalable microfluidic mixing platform to produce SqGem-based NPs and evaluated the stability and morphology of select NP formulations using dynamic light scattering (DLS) and transmission electron microscopy (TEM). Cytotoxicity was evaluated in both PANC-1 and KPC (KrasLSL-G12D/+; Trp53LSL-R172H/+; Pdx-Cre) pancreatic cancer cell lines. A 64Cu chelator (2-S-(4-aminobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid, NOTA) was squalenoylated and used with positron emission tomography (PET) imaging to monitor the in vivo fate of SqGem-based NPs. Results: Squalenoylation yields of gemcitabine increased from 15% to 63%. Cholesterol-PEG-2k inclusion was required to form SqGem-based NPs using our technique, and additional cholesterol inclusion increased particle stability at room temperature; after 1 week the PDI of SqGem NPs with cholesterol was ~ 0.2 while the PDI of SqGem NPs lacking cholesterol was ~ 0.5. Similar or superior cytotoxicity was achieved for SqGem-based NPs compared to gemcitabine or Abraxane® when evaluated at a concentration of 10 µM. Squalenoylation of NOTA enabled in vivo monitoring of SqGem-based NP pharmacokinetics and biodistribution. Conclusion: We present a scalable technique for fabricating efficacious squalenoylated-gemcitabine nanoparticles and confirm their pharmacokinetic profile using a novel multifunctional 64Cu-SqNOTA-SqGem NP.
Collapse
Affiliation(s)
- Samantha T Tucci
- Department of Biomedical Engineering, University of California Davis, Davis, California, 95616, USA
| | - Jai W Seo
- Department of Radiology, Stanford University, Palo Alto, CA 94304, USA
| | - Hamilton Kakwere
- Department of Radiology, Stanford University, Palo Alto, CA 94304, USA
| | | | - Elizabeth S Ingham
- Department of Biomedical Engineering, University of California Davis, Davis, California, 95616, USA
| | - Lisa M Mahakian
- Department of Biomedical Engineering, University of California Davis, Davis, California, 95616, USA
| | - Sarah Tam
- Department of Biomedical Engineering, University of California Davis, Davis, California, 95616, USA
| | - Spencer Tumbale
- Department of Radiology, Stanford University, Palo Alto, CA 94304, USA
| | - Mo Baikoghli
- Department of Molecular and Cellular Biology, University of California Davis, Davis, California, 95616, USA
| | - R Holland Cheng
- Department of Molecular and Cellular Biology, University of California Davis, Davis, California, 95616, USA
| | | |
Collapse
|
2
|
Wang L, Ma Y, Gu Y, Liu Y, Zhao J, Yan B, Wang Y. Cryoprotectant choice and analyses of freeze-drying drug suspension of nanoparticles with functional stabilisers. J Microencapsul 2018; 35:241-248. [DOI: 10.1080/02652048.2018.1462416] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- Lulu Wang
- School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China
| | - Yingying Ma
- School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China
| | - Yu Gu
- School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China
| | - Yangyang Liu
- School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China
| | - Juan Zhao
- School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China
| | - Beibei Yan
- School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China
| | - Yancai Wang
- School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China
| |
Collapse
|
3
|
Rodríguez-Nogales C, Garbayo E, Martínez-Valbuena I, Sebastián V, Luquin MR, Blanco-Prieto MJ. Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein. Int J Pharm 2017; 514:142-149. [PMID: 27863657 DOI: 10.1016/j.ijpharm.2016.06.044] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Revised: 06/16/2016] [Accepted: 06/17/2016] [Indexed: 10/20/2022]
Abstract
Polo like kinase 2 (PLK2), a serine/threonine serum inducible kinase, has been proposed to be the major factor responsible for phosphorylating alpha-synuclein (α-syn) at Serine-129 (Ser-129) in Parkinson's disease (PD). A suitable strategy to gain insights into PLK2's biological effects might be to increase PLK2 intracellular levels with the aim of reproducing the slow progressive neuronal changes that occur in PD. The goal of this study was to develop and characterize a novel drug delivery system (DDS) for PLK2 cytosolic delivery using Total recirculating one machine system (TROMS), a technique capable of encapsulating fragile molecules while maintaining their native properties. A protocol for nanoparticle (NP) preparation using TROMS was set up. NPs showed a mean diameter of 257±15.61nm and zeta potential of -16±2mV, suitable for cell internalization. TEM and SEM images showed individual, spherical, dispersed NPs. The drug entrapment efficacy was 61.86±3.9%. PLK2-NPs were able to enter SH-SY5Y cells and phosphorylate α-syn at Ser-129, demonstrating that the enzyme retained its activity after the NP manufacturing process. This is the first study to develop a DDS for continuous intracellular delivery of PLK2. These promising results indicate that this novel nanotechnology approach could be used to elucidate the biological effects of PLK2 on dopaminergic neurons.
Collapse
Affiliation(s)
- C Rodríguez-Nogales
- Pharmacy and Pharmaceutical Technology Department, University of Navarra, Pamplona, Spain
| | - E Garbayo
- Pharmacy and Pharmaceutical Technology Department, University of Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain
| | | | - V Sebastián
- Chemical & Environmental Engineering Department & Nanoscience Institute of Aragon, University of Zaragoza, Zaragoza, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Madrid, Spain
| | - M R Luquin
- Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain; Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain
| | - M J Blanco-Prieto
- Pharmacy and Pharmaceutical Technology Department, University of Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.
| |
Collapse
|
4
|
Gaudin A, Song E, King AR, Saucier-Sawyer JK, Bindra R, Desmaële D, Couvreur P, Saltzman WM. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma. Biomaterials 2016; 105:136-144. [PMID: 27521616 DOI: 10.1016/j.biomaterials.2016.07.037] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2016] [Revised: 07/27/2016] [Accepted: 07/29/2016] [Indexed: 11/25/2022]
Abstract
New treatments for glioblastoma multiforme (GBM) are desperately needed, as GBM prognosis remains poor, mainly due to treatment resistance, poor distribution of therapeutics in the tumor tissue, and fast metabolism of chemotherapeutic drugs in the brain extracellular space. Convection-enhanced delivery (CED) of nanoparticles (NPs) has been shown to improve the delivery of chemotherapeutic drugs to the tumor bed, providing sustained release, and enhancing survival of animals with intracranial tumors. Here we administered gemcitabine, a nucleoside analog used as a first line treatment for a wide variety of extracranial solid tumors, within squalene-based NPs using CED, to overcome the above-mentioned challenges of GBM treatment. Small percentages of poly(ethylene) glycol (PEG) dramatically enhanced the distribution of squalene-gemcitabine nanoparticles (SQ-Gem NPs) in healthy animals and tumor-bearing animals after administration by CED. When tested in an orthotopic model of GBM, SQ-Gem-PEG NPs demonstrated significantly improved therapeutic efficacy compared to free gemcitabine, both as a chemotherapeutic drug and as a radiosensitizer. Furthermore, MR contrast agents were incorporated into the SQ-Gem-PEG NP formulation, providing a way to non-invasively track the NPs during infusion.
Collapse
Affiliation(s)
- Alice Gaudin
- Department of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA
| | - Eric Song
- Department of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA
| | - Amanda R King
- Department of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA
| | | | - Ranjit Bindra
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, 06511, USA
| | - Didier Desmaële
- Institut Galien Paris-Sud, UMR CNRS 8612, University Paris-Sud XI, Châtenay-Malabry, 92290, France
| | - Patrick Couvreur
- Institut Galien Paris-Sud, UMR CNRS 8612, University Paris-Sud XI, Châtenay-Malabry, 92290, France
| | - W Mark Saltzman
- Department of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA.
| |
Collapse
|
5
|
Lakkadwala S, Nguyen S, Lawrence J, Nauli SM, Nesamony J. Physico-chemical characterisation, cytotoxic activity, and biocompatibility studies of tamoxifen-loaded solid lipid nanoparticles prepared via a temperature-modulated solidification method. J Microencapsul 2014; 31:590-9. [DOI: 10.3109/02652048.2014.898707] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
6
|
Desmaële D, Gref R, Couvreur P. Squalenoylation: A generic platform for nanoparticular drug delivery. J Control Release 2012; 161:609-18. [DOI: 10.1016/j.jconrel.2011.07.038] [Citation(s) in RCA: 106] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2011] [Revised: 07/22/2011] [Accepted: 07/23/2011] [Indexed: 01/02/2023]
|
7
|
Ghaffari S, Varshosaz J, Haririan I, Khoshayand MR, Azarmi S, Gazori T. Ciprofloxacin Loaded Alginate/Chitosan and Solid Lipid Nanoparticles, Preparation, and Characterization. J DISPER SCI TECHNOL 2012. [DOI: 10.1080/01932691.2011.579831] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
8
|
Fang JY, Al-Suwayeh SA. Nanoparticles as delivery carriers for anticancer prodrugs. Expert Opin Drug Deliv 2012; 9:657-69. [DOI: 10.1517/17425247.2012.679927] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
9
|
Celia C, Cosco D, Paolino D, Fresta M. Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. Expert Opin Drug Deliv 2011; 8:1609-29. [PMID: 22077480 DOI: 10.1517/17425247.2011.632630] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Gemcitabine, an anticancer drug, is a nucleoside analog deoxycytidine antimetabolite, which acts against a wide range of solid tumors. The limitation of gemcitabine is its rapid inactivation by the deoxycytidine deaminase enzyme following its in vivo administration. AREAS COVERED One of the most promising new approaches for improving the biopharmaceutical properties of gemcitabine is the use of innovative drug delivery devices. This review explains the current status of gemcitabine drug delivery, which has been under development over the past 5 years, with particular emphasis on liposomal delivery. In addition, the use of novel supramolecular vesicular aggregates (SVAs), polymeric nanoparticles and squalenoylation were treated as interesting innovative approaches for the administration of the nucleoside analog. EXPERT OPINION Different colloidal systems containing gemcitabine have been realized, with the aim of providing important potential advancements through traditional ways of therapy. A possible future commercialization of modified gemcitabine is desirable, as was true in the case of liposomal doxorubicin (Doxil(®), Caely(®)).
Collapse
Affiliation(s)
- Christian Celia
- The Methodist Hospital Research Institute, Department of Nanomedicine, 6670 Bertner St, Houston, TX 77030, USA
| | | | | | | |
Collapse
|
10
|
Bang EK, Moon DH, Kim BH. Spontaneous Nanoparticle Formation From a Fluorescent Nucleoside Analogue. B KOREAN CHEM SOC 2011. [DOI: 10.5012/bkcs.2011.32.8.2906] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
11
|
Caron J, Lepeltier E, Reddy LH, Lepêtre-Mouelhi S, Wack S, Bourgaux C, Couvreur P, Desmaële D. Squalenoyl Gemcitabine Monophosphate: Synthesis, Characterisation of Nanoassemblies and Biological Evaluation. European J Org Chem 2011. [DOI: 10.1002/ejoc.201100036] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
12
|
Wang P, Li C, Gong H, Jiang X, Wang H, Li K. Effects of synthesis conditions on the morphology of hydroxyapatite nanoparticles produced by wet chemical process. POWDER TECHNOL 2010. [DOI: 10.1016/j.powtec.2010.05.023] [Citation(s) in RCA: 207] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: An original drug delivery pathway. J Control Release 2010; 147:163-70. [DOI: 10.1016/j.jconrel.2010.07.120] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2010] [Revised: 07/17/2010] [Accepted: 07/27/2010] [Indexed: 11/22/2022]
|
14
|
Azizi E, Namazi A, Haririan I, Fouladdel S, Khoshayand MR, Shotorbani PY, Nomani A, Gazori T. Release profile and stability evaluation of optimized chitosan/alginate nanoparticles as EGFR antisense vector. Int J Nanomedicine 2010; 5:455-61. [PMID: 20957167 PMCID: PMC2950403 DOI: 10.2147/ijn.s9551] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2010] [Indexed: 11/30/2022] Open
Abstract
Chitosan/alginate nanoparticles which had been optimized in our previous study using two different N/P ratios were chosen and their ability to release epidermal growth factor receptor (EGFR) antisense was investigated. In addition, the stability of these nanoparticles in aqueous medium and after freeze-drying was investigated. In the case of both N/P ratios (5, 25), nanoparticles started releasing EGFR antisense as soon as they were exposed to the medium and the release lasted for approximately 50 hours. Nanoparticle size, shape, zeta potential, and release profile did not show any significant change after the freeze-drying process (followed by reswelling). The nanoparticles were reswellable again after freeze-drying in phosphate buffer with a pH of 7.4 over a period of six hours. Agarose gel electrophoresis of the nanoparticles with the two different N/P ratios showed that these nanoparticles could protect EGFR antisense molecules for six hours.
Collapse
Affiliation(s)
- Ebrahim Azizi
- Molecular Research Lab, Department of Pharmacology and Toxicology, Tehran University of Medical Sciences, Tehran, Iran
| | | | | | | | | | | | | | | |
Collapse
|